These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 19681866)

  • 1. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
    Grieve DJ; Cassidy RS; Green BD
    Br J Pharmacol; 2009 Aug; 157(8):1340-51. PubMed ID: 19681866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
    Anagnostis P; Athyros VG; Adamidou F; Panagiotou A; Kita M; Karagiannis A; Mikhailidis DP
    Diabetes Obes Metab; 2011 Apr; 13(4):302-12. PubMed ID: 21205117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based therapies: can we achieve glycemic control and cardioprotection?
    Angeli FS; Shannon RP
    J Endocrinol; 2014 Apr; 221(1):T17-30. PubMed ID: 23926280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cardiovascular effects of GLP-1 receptor agonists.
    Okerson T; Chilton RJ
    Cardiovasc Ther; 2012 Jun; 30(3):e146-55. PubMed ID: 21167014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular biology of the incretin system.
    Ussher JR; Drucker DJ
    Endocr Rev; 2012 Apr; 33(2):187-215. PubMed ID: 22323472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1 based therapy for type 2 diabetes.
    Yu BS; Wang AR
    World J Pediatr; 2008 Feb; 4(1):8-13. PubMed ID: 18402245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-mediated control of cardiac energy metabolism.
    Chan JSF; Shafaati T; Ussher JR
    J Endocrinol; 2024 Oct; 263(1):. PubMed ID: 39013412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.
    Verge D; López X
    Curr Diabetes Rev; 2010 Jul; 6(4):191-200. PubMed ID: 20380625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.
    Heuvelman VD; Van Raalte DH; Smits MM
    Cardiovasc Res; 2020 Apr; 116(5):916-930. PubMed ID: 31825468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretins and Their Endocrine and Metabolic Functions.
    Seufert J
    Endocr Dev; 2017; 32():38-48. PubMed ID: 28873383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of glucagon-like peptide 1 on cardiovascular risk.
    Sivertsen J; Rosenmeier J; Holst JJ; Vilsbøll T
    Nat Rev Cardiol; 2012 Jan; 9(4):209-22. PubMed ID: 22290234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretins and cardiovascular disease: to the heart of type 2 diabetes?
    Solini A; Tricò D; Del Prato S
    Diabetologia; 2023 Oct; 66(10):1820-1831. PubMed ID: 37542009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
    Madsbad S
    Diabetes Obes Metab; 2014 Jan; 16(1):9-21. PubMed ID: 23617798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
    Van Gaal LF; Gutkin SW; Nauck MA
    Eur J Endocrinol; 2008 Jun; 158(6):773-84. PubMed ID: 18322302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.